Clinical trials
Pharmacokinetics and Pharmacodynamics clinical trials
Below are recruiting pharmacokinetics and pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 142 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06692933RecruitingEarly Phase 1
How hemp affects a common blood thinner
This study tests if a hemp product changes how the body processes the blood thinner clopidogrel (Plavix). You must be healthy, have used cannabis before without problems, and have a specific gene type that affects how these substances break down.
Spokane, WashingtonAges 21–64 - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07201467RecruitingPhase 1/Phase 2
KN060 for dialysis patients with kidney failure
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
Beijing, Beijing MunicipalityAges 18–80 - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT07559136RecruitingPhase 1
Safety study of HRS9531 injection for teen obesity
This study tests whether a new injectable medication called HRS9531 is safe and well-tolerated in teenagers aged 12–17 with obesity. Researchers will monitor how your body handles the medication and whether it affects your weight.
Wuhan, HubeiAges 12–18 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT07702890RecruitingPhase 1/Phase 2
Testing a new drug for obesity and type 2 diabetes
This trial tests an investigational drug called GUB-UCN2 in people who are healthy, overweight, or have type 2 diabetes. The goal is to see if the drug is safe and how the body processes it.
NeussAges 18–75 - NCT07271693RecruitingPhase 1
Safety study of a new medicine in healthy volunteers
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
ChristchurchAges 18–50 - NCT07721597RecruitingEarly Phase 1
Testing ZP6590 in Men of Various Weights
This trial tests an experimental medication called ZP6590 given as injections. It's for men who are at a normal weight, overweight, or have obesity, and studies how safe and well-tolerated the drug is in different doses.
Neuss, North Rhine-WestphaliaAges 18–60 - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT07567872RecruitingPhase 1
Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Chengdu, SichuanAges 18–75 - NCT04216342RecruitingPhase 1
Testing a new breathing-drug ingredient in healthy adults
This early study (Phase 1) tests how safe and tolerable Fx-5A is, and how the body processes it, in healthy volunteers. It’s mainly looking to understand side effects and drug levels rather than treating a disease.
Bethesda, MarylandAges 18–99 - NCT03708900RecruitingPhase 2
Osilodrostat study for children with Cushing’s syndrome
This Phase 2 study tests how osilodrostat works in children and teens with Cushing’s syndrome—what the drug does in the body, how it affects hormones, and how safely it’s tolerated. It may help families who cannot have immediate surgery or whose surgery has already failed or is still pending.
San Francisco, CaliforniaAges 2–17 - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT05127226RecruitingPhase 1/Phase 2
Test drug safety for Angelman syndrome in young children
This early-phase study tests a new experimental medicine called ION582 to see if it is safe, tolerable, and how the body processes it in people with Angelman syndrome. It may also look at early signs of how the medicine affects the brain and body, which could guide future treatments.
San Diego, CaliforniaAges birth–50 years - NCT05482789RecruitingPhase 4
Exenatide study in pregnancy-related diabetes without medicines
This trial studies how exenatide affects blood sugar in pregnant people with gestational diabetes who do not need medication yet. The goal is to understand how the medicine works in the body during pregnancy, which may help improve future treatment decisions.
Pittsburgh, PennsylvaniaAges 18–50 - NCT05702463RecruitingPhase 1
Daily aspirin in adults with type 2 diabetes
This early-stage study tests how a daily aspirin tablet behaves in the body and how it affects blood/clotting markers in people with type 2 diabetes. It may help researchers understand whether this form of aspirin could be useful, especially if you’re not currently taking aspirin.
Montreal, QuebecAges 18 years+ - NCT05962229RecruitingPhase 1
Testing how synthetic nicotine is processed in regular e-cig users
This Phase 1 study tests how a synthetic nicotine product is absorbed and how the body responds (so researchers can better understand nicotine effects and handling). You may be able to join if you’re generally healthy and regularly use e-cigarettes, but you’ll need to avoid certain medicines and nicotine products during the study.
San Francisco, CaliforniaAges 21–65 - NCT06089980Recruiting
Kratom product study for regular users
This study watches how regular kratom users react to their own kratom product. It aims to learn more about kratom's effects in real-world settings.
Baltimore, MarylandAges 21 years+ - NCT06150716RecruitingPhase 1
Study of a new drug for Pelizaeus Merzbacher disease in boys
This trial is testing an experimental drug (ION356) given by a lumbar puncture to see if it is safe and how it works in boys with Pelizaeus Merzbacher disease (PMD). The drug is designed to target the genetic cause of PMD.
Atlanta, GeorgiaAges 2–17 - NCT06153966RecruitingPhase 1/Phase 2
Study of ION717 for early-stage prion disease
This trial tests an investigational drug called ION717 in people with early-stage prion disease. The goal is to see if it is safe and how the body processes it.
Boston, MassachusettsAges 18 years+ - NCT06324604RecruitingPhase 1
Safety study of MTX-101 in healthy adults
This trial tests a new drug called MTX-101 in healthy volunteers to see if it is safe and how the body processes it. It helps determine the right dose before testing in patients with certain conditions.
Heidelberg, VictoriaAges 18–65
Hear when a new Pharmacokinetics and Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacokinetics and pharmacodynamics?
- Yes. Clin2 currently lists 142 recruiting pharmacokinetics and pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacokinetics and pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacokinetics and pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.